Conference Coverage: ASH 2022 – Focus on Leukemia
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia.
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Rami Komrokji, MD
H. Lee Moffitt Cancer Center, Tampa, FL, USA
Valeria Santini, MD
University of Florence, Italy
Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci
Queen Elizabeth Hospital, Birmingham, UK
Gail J. Roboz, MD
Weill Cornell Medicine, New York, NY, USA
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA, USA
Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
REPORT SNAPSHOT
- New Developments in Myelodysplastic Syndromes (MDS)
- Advances in Acute Myeloid Leukemia (AML): Newly Diagnosed
- Advances in AML: Relapsed/Refractory (R/R)
- Advances in Acute Lymphoblastic Leukemia (ALL): Newly Diagnosed
- Advances in ALL: Relapsed/Refractory
